Kisho is an information platform, not a medical provider. Nothing on this site constitutes medical advice, diagnosis, or treatment recommendations. All content is aggregated from publicly available sources (including ClinicalTrials.gov, PubMed, FDA.gov, and Orphanet) and is provided for informational purposes only. Clinical trial eligibility, treatment decisions, and any health-related actions should always be discussed with a qualified healthcare professional. Kisho does not endorse any specific therapy, organization, or clinical trial. Terms of use · Privacy policy
TMEM165-CDG is a form of congenital disorders of N-linked glycosylation characterized by a psychomotor delay-dysmorphism (pectus carinatum, dorsolumbar kyphosis and severe sinistroconvex scoliosis, short distal phalanges, genua vara, pedes planovalgi syndrome) with postnatal growth deficiency and major spondylo-, epi-, and metaphyseal skeletal involvement. Additional features include facial dysmorphism (midface hypoplasia, internal strabism of the right eye, low-set ears, moderately high arched palate, small teeth), nephrotic syndrome, cardiac defects, and feeding problems. The disease is caused by mutations in the gene TMEM165 (4q12).
Features include always present findings: Elevated creatine kinase (muscle enzyme) (elevated circulating creatine kinase concentration), Low muscle tone (hypotonia), Enlarged liver (hepatomegaly), and Diaphyseal dysplasia and others; and common findings: Elevated circulating alanine aminotransferase concentration and Low platelet count (thrombocytopenia). 27 total HPO annotations.
Organ System | Phenotype Count | Example Features |
|---|---|---|
Lab test results | 3 |
TMEM165 function has not been fully characterized.
TMEM165-congenital disorder of glycosylation is associated with mutations in the TMEM165 gene on chromosome 4.
Genetic testing for TMEM165 is available. Testing is considered confirmatory for diagnosis.
Biomarker and diagnostic research for TMEM165-congenital disorder of glycosylation has been reported in the published literature.
Phenotype severity distribution: 12 always present features, 2 common features.
Estimated prevalence: <1 in 1,000,000 (VERY_RARE).
No clinical trials have been registered for TMEM165-congenital disorder of glycosylation.
251 publications have been identified in PubMed for TMEM165-congenital disorder of glycosylation. Research spans Basic Science / Preclinical (44%), Review / Meta-Analysis (42%), and Epidemiology / Natural History (5%).
Research Type | Count | % of Total |
|---|---|---|
Laboratory research | 111 | 44% |
Data assembled from 6 of 12 sources · Last updated Sep 21, 2026, 4:53 AM UTC
Online Mendelian Inheritance in Man
European rare disease database
Genetic and Rare Diseases Info Center
Common questions about TMEM165-congenital disorder of glycosylation
Growth and development | 3 | Short stature, Failure to thrive, Growth delay |
Brain and nerves | 3 | Seizure, Global developmental delay, Abnormal brain white matter (abnormal cerebral white matter morphology) |
Bones and joints | 3 | Weak and brittle bones (osteoporosis), Kyphoscoliosis, Joint hypermobility |
Blood and immune system | 2 | Hemolytic-uremic syndrome, Low platelet count (thrombocytopenia) |
Muscles | 2 | Low muscle tone (hypotonia), Muscle weakness |
Digestive system | 1 | Enlarged liver (hepatomegaly) |
Head and neck | 1 | Secondary microcephaly |
Metabolism | 1 | Unexplained fevers |
Research summaries
106 |
42% |
Disease patterns and progression | 12 | 5% |
Testing and diagnosis research | 9 | 4% |
Patient case studies | 6 | 2% |
New treatment approaches | 4 | 2% |
Other research | 2 | 1% |
Clinical study results | 1 | 0% |
Ünsal Y (2026). [PMID: 39975416](https://pubmed.ncbi.nlm.nih.gov/39975416/). *J Clin Res Pediatr Endocrinol*. [Review / Meta-Analysis]
Damiano C (2026). [PMID: 41554119](https://pubmed.ncbi.nlm.nih.gov/41554119/). *J Inherit Metab Dis*. [Basic Science / Preclinical]
Sodano F (2026). [PMID: 41968365](https://pubmed.ncbi.nlm.nih.gov/41968365/). *IUBMB Life*. [Gene Therapy / Novel Therapeutics]
Fu B (2026). [PMID: 41559085](https://pubmed.ncbi.nlm.nih.gov/41559085/). *Nat Commun*. [Diagnostic / Biomarker]
Sumya FT (2026). [PMID: 41718976](https://pubmed.ncbi.nlm.nih.gov/41718976/). *Subcell Biochem*. [Review / Meta-Analysis]
Gleeson PA (2026). [PMID: 41713215](https://pubmed.ncbi.nlm.nih.gov/41713215/). *Biochim Biophys Acta Gen Subj*. [Review / Meta-Analysis]
Al-Shahrani H (2026). [PMID: 41897354](https://pubmed.ncbi.nlm.nih.gov/41897354/). *Biomolecules*. [Case Report / Case Series]
Yan R (2026). [PMID: 41727429](https://pubmed.ncbi.nlm.nih.gov/41727429/). *Front Immunol*. [Review / Meta-Analysis]
Yang F (2026). [PMID: 41730107](https://pubmed.ncbi.nlm.nih.gov/41730107/). *Proc Natl Acad Sci U S A*. [Basic Science / Preclinical]
Johannes L (2026). [PMID: 41173705](https://pubmed.ncbi.nlm.nih.gov/41173705/). *Trends Cell Biol*. [Review / Meta-Analysis]